Table 2.
Stool bile acids (BAs) in primary sclerosing cholangitis associated with inflammatory bowel disease (PSC-IBD) and inflammatory bowel disease (IBD) patients.
| BAs | PSC-IBD | IBD | p value |
|---|---|---|---|
| Primary BAs | 9.5 (18) | 4.2 (15.2) | 0.29 |
| Secondary BAs | 89.4 (24.6) | 91.2 (15.1) | 0.57 |
| CA | 4.6 (6.45) | 1.49 (4.77) | 0.06 |
| CDCA | 4.73 (10.4) | 2.72 (11.0) | 1.0 |
| DCA | 52.5 (23.5) | 43.6 (14.3) | 0.55 |
| LCA | 34.1 (33.8) | 46.2 (1.9) | 0.14 |
| UDCA | 1.1 (1.9) | 1.8 (3.9) | 0.37 |
| Tauro/glyco conjugates | 0.47 (0.67) | 0.34 (0.69) | 0.98 |
| Sulfated BAs | 2.1 (3.1) | 2.4 (16.3) | 0.41 |
| Conjugated BAs | 4.5 (13.7) | 2.7 (6.9) | 0.23 |
CA: cholic acid; CDCA: chenodeoxycholic acid; DCA: deoxycholic acid; LCA: litocholic acid; UDCA: ursodeoxycholic acid.
BAs are expressed as percentage median (interquartile range) of total BAs. Distributions were compared with non-parametric tests (Mann–Whitney). Due to a small amount of minor BA species in stool (muricholic acid, hycholic acid, hyodeoxycholic acid, or ursodeoxhycolic acid) which are considered by some authors as ‘tertiary BAs’, the sum of primary and secondary BAs is not 100%.